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Juan R. Gimeno, MD, PHD,c,g Lorenzo Monserrat, MD, PHDaABSTRACTISSBACKGROUND The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of
cases. Formin homology 2 domain containing 3 (FHOD3) may have a role in the pathogenesis of cardiac hypertrophy but
has not been implicated in hypertrophic cardiomyopathy.
OBJECTIVES This study sought to investigate the relation between FHOD3 mutations and the development of hy-
pertrophic cardiomyopathy.
METHODS FHOD3 was sequenced by massive parallel sequencing in 3,189 hypertrophic cardiomyopathy unrelated
probands and 2,777 patients with no evidence of cardiomyopathy (disease control subjects). The authors evaluated
protein-altering candidate variants in FHOD3 for cosegregation, clinical characteristics, and outcomes.
RESULTS The authors identiﬁed 94 candidate variants in 132 probands. The variants’ frequencies were signiﬁcantly
higher in patients with hypertrophic cardiomyopathy (74 of 3,189 [2.32%]) than in disease control subjects (18 of 2,777
[0.65%]; p < 0.001) or in the gnomAD database (1,049 of 138,606 [0.76%]; p < 0.001). FHOD3 mutations cosegre-
gated with hypertrophic cardiomyopathy in 17 families, with a combined logarithm of the odds score of 7.92, indicative of
very strong segregation. One-half of the disease-causing variants were clustered in a small conserved coiled-coil domain
(amino acids 622 to 655); odds ratio for hypertrophic cardiomyopathy was 21.8 versus disease control subjects
(95% conﬁdence interval: 1.3 to 37.9; p < 0.001) and 14.1 against gnomAD (95% conﬁdence interval: 6.9 to 28.7; p <
0.001). Hypertrophic cardiomyopathy patients carrying (likely) pathogenic mutations in FHOD3 (n ¼ 70) were diagnosed
after age 30 years (mean 46.1 18.7 years), and two-thirds (66%)weremales. Of the patients, 82%had asymmetric septal
hypertrophy (mean 18.8  5 mm); left ventricular ejection fraction <50% was present in 14% and hypertrabeculation in
16%. Events were rare before age 30 years, with an annual cardiovascular death incidence of 1% during follow-up.
CONCLUSIONS FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2%
of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The
FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels. (J Am Coll Cardiol
2018;72:2457–67) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2018.10.001
ABBR EV I A T I ON S
AND ACRONYMS
DCM = dilated cardiomyopathy
FHOD3 = formin homology 2
domain containing 3 gene
GWAS = genome-wide
association studies
HCM = hypertrophic
cardiomyopathy
LOD = logarithm of the odds
MAF = minor allele frequency
SCD = sudden cardiac death
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2458H ypertrophic cardiomyopathy(HCM) is the most commoninherited cardiomyopathy and is
characterized by clinical variability and ge-
netic heterogeneity (1). The introduction of
massive parallel sequencing has improved
the understanding of the disease, but >40%
of genetic studies reveal no pathogenic
mutation, suggesting that new disease-
associated genes remain to be discovered.
One potential candidate is formin homology
2 domain containing 3 (FHOD3) gene.SEE PAGE 2468Formins are a family of proteins containing a
series of conserved domains and functional motifs
that regulate actin dynamics (2). FHOD3 protein is
expressed exclusively in the heart and plays an
important role in sarcomere organization, myoﬁ-
brillogenesis, and maintenance of the contractile
apparatus in cardiomyocytes (3,4). Functional and
genome-wide association studies (GWAS) have
suggested a potential role of FHOD3 in theaHealth in Code S.L., Scientiﬁc Department, A Coruña, Spain; b
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At the beginning of 2014, we included FHOD3 in
genetic panels used to screen patients with inherited
cardiomyopathies. After detecting an FHOD3 variant
that segregated with HCM in a large Spanish family,
we performed a systematic evaluation of FHOD3
mutations in a larger cohort of patients and in a
control population.
METHODS
From February 2014 to August 2017, FHOD3 was
sequenced using next-generation sequencing in
7,881 consecutive unrelated probands with a diag-
nosis of different inherited cardiac conditions
referred to our center for molecular genetic diag-
nosis. The phenotypes were established by each
center prior to the genetic studies. Patients’ samples
were referred mainly from centers from Spain, fol-
lowed by centers from the United Kingdom,
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2459Of the probands, 3,189 had a diagnosis of HCM. An
additional 2,777 index cases with no evidence of
structural cardiac disease (mainly channelopathies
and aortic diseases) were used as control subjects.
The predominant ethnicity was European (>90% of
the probands), and there were no differences be-
tween HCM probands and control subjects. The
variants’ frequencies in the general population were
extracted from the gnomAD database version r2.0,
August 2017 (6).
In the initial screening phase, candidate variants in
FHOD3 were identiﬁed and their frequencies
compared in HCM versus control subgroups. We
applied an MAF (minor allele frequency) threshold of
5  105 to consider a variant a candidate, following
the same arguments used by Walsh et al. (7) to reas-
sess gene pathogenicity in cardiomyopathies; we also
excluded variants with an MAF $1 104 in any sub-
population of gnomAD to avoid variants detected in
cases could be enriched in 1 speciﬁc population. Only
unrelated index cases were included in the screening
phase of the study. Patients with cardiomyopathies
other than HCM and sudden cardiac death (SCD) vic-
tims were excluded from the analysis.
In the second phase, HCM probands carrying
candidate variants in FHOD3 were invited to partici-
pate in segregation studies. Clinical and genetic fa-
milial cascade screening was performed following
written informed consent in those who agreed to
participate. Carriers of variants in other sarcomeric
genes that could be related to the phenotype (path-
ogenic, likely pathogenic, or of uncertain signiﬁcance
in a priority gene) were excluded. The clinical char-
acteristics and outcomes in carriers of pathogenic or
likely pathogenic variants in FHOD3 with HCM
(including probands and relatives) were assessed. The
study protocol was approved by the Research Ethics
Committee of A Coruña-Ferrol (registry code 2015/
576).
GENETIC STUDIES, VARIANT FILTERING, AND
VARIANT CLASSIFICATION. Coding exons and
intronic boundaries of 213 genes related to inherited
cardiovascular diseases and SCD (Online Table 1)
were captured using a custom probe library (Sure-
Select Target Enrichment Kit for Illumina paired-end
multiplexed sequencing method, Agilent Technolo-
gies, Santa Clara, California) and sequenced using
the HiSeq 1500 platform (Illumina, San Diego, Cali-
fornia) following lllumina protocols. The read depth
(number of times that a base was sequenced by
independent reads) of every nucleotide of genes
related to the referring phenotype (including FHOD3)
was >30 (mean 250 to 400). Exons that didnot fulﬁll this standard were complementary
sequenced using the Sanger method. Only likely
protein-altering variants (missense, in-frame in-
sertions/deletions, frameshift, nonsense, and
consensus splice site mutations) in the most rele-
vant, longest transcript of the FHOD3 gene
(NM_001281740.1; 1,644 amino acids) were analyzed.
Bioinformatics analysis was performed by means of a
custom pipeline including software for variant call-
ing, genotyping, and annotation.
To establish the pathogenicity of identiﬁed vari-
ants, we developed a customized classiﬁcation
scheme based on the recommendations of the Amer-
ican College of Medical Genetics and Genomics
(Online Table 2) (8); the ﬁnal classiﬁcation of each
variant was agreed by consensus between 2 cardiol-
ogists with experience in interpretation of genetic
variants.
STATISTICAL ANALYSIS. Continuous variables were
expressed as mean  SD, and comparison between
groups was performed using the Student’s t-test or
the Mann-Whitney U test according to values distri-
bution. Noncontinuous variables were expressed as
an integer number (percent of total) and compared
using the chi-square test or Fisher exact test, as
appropriate. A 2-sided p value <0.05 was considered
to indicate statistical signiﬁcance. Analysis was per-
formed using R version 3.4.3 (R Foundation for Sta-
tistical Computing, Vienna, Austria).
LOGARITHMS OF ODDS SCORE CALCULATION. We
calculated 2-point logarithm of the odds (LOD) score
for informative families by using the PARAMLINK
package for R software (9). The model was set with
q ¼ 0, phenocopy rate ¼ 0.005, and 2 different
penetrance values: 0.80 and 0.95. An indeterminate
status was assigned to family members with a con-
founding cardiac diagnosis, as well as to men younger
than age 45 years and women younger than age 50
years who did not meet clinical criteria for HCM and
could develop the disease afterwards.
SURVIVAL ANALYSIS. The cumulative probability of
cardiovascular death in carriers of disease-causing
mutations in FHOD3 after a diagnosis of HCM
(follow-up) was estimated using the Kaplan-Meier
method. Cardiovascular death was deﬁned as the
presence of sudden cardiac death, appropriate deﬁ-
brillator shock, heart failure death, or heart trans-
plantation. The beginning of the follow-up was
established as the ﬁrst clinical visit when the patient
had a diagnosis of the disease (unaffected carriers and
SCD cases in which HCM was diagnosed postmortem
were excluded from this analysis).
FIGURE 1 Flow Chart of the Screening and Segregation Phases of the Study
FHOD3 variants
n = 94
FHOD3 variants
n = 47
Probands (all group)
n = 132
HCM Probands
n = 74
Familial Evaluation
n = 30
Other phenotypes
n = 35
Controls
n = 18
Phenotype unavailable
n = 5
Sporadic Cases
n = 5
Segregation Uncertain
n = 6
Segregation Unlikely
n = 2
P / LP
n = 12
Other variants in
sarcomeric genes
PHASE 1
SCREENING
SEGREGATION
PHASE 2
VUS
n = 2
Declined to participate
n = 11
Relatives unavailable
n = 19
HCM Probands Eligible
(no other candidate variants)
n = 60
HCM Probands Recruited
(accepted segregation)
n = 49
Segregation
Definitive/Likely
n = 17
FHOD3 Disease Causing Variants
in 1.1% of cases of HCM cohort
(35 probands)
FHOD3 variants
n = 28
13 FHOD3 Pathogenic Variants
Combined LODs = 7.92
FHOD3 ¼ formin homology 2 domain containing 3 gene; HCM ¼ hypertrophic cardiomyopathy; P/LP ¼ pathogenic/likely pathogenic;
SCD ¼ sudden cardiac death; VUS ¼ variant of uncertain signiﬁcance.
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2460RESULTS
STUDY POPULATION. A total of 94 candidate vari-
ants in FHOD3 distributed in 132 probands were
identiﬁed, representing 1.67% of the 7,881 consecu-
tive unrelated probands who were sequenced. Of
these variants, 90 were nontruncating (88 missense,2 in-frame deletion/insertion) and 4 were truncating
(3 nonsense, 1 frameshift). HCM was the diagnosis in
74 of the 132 probands (56.1%) who carried a candi-
date variant in FHOD3. In 5 probands the phenotype
was unavailable, and 18 individuals were control
subjects without evidence of structural cardiac dis-
ease. A total of 35 patients were excluded from the
FIGURE 2 Pedigree of a Multigenerational Spanish Family
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The p.Tyr528Cys variant in FHOD3 was identiﬁed independently in 4 index cases belonging to 4 nuclear subfamilies (arrows) from the same region of Murcia, Spain.
A subsequent genealogic analysis determined that they were descendants of a common ancestor born 7 generations ago.
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2461analysis: 27 patients had a diagnosis of a cardiomy-
opathy other than HCM (18 dilated cardiomyopathy
[DCM], 5 arrhythmogenic cardiomyopathy, 3 left
ventricular noncompaction, and 1 restrictive cardio-
myopathy), while 8 patients were SCD victims. A
detailed description of the variants, population fre-
quencies, bioinformatics predictors, initial estimation
of pathogenicity, and the phenotype in carriers are
shown in Online Table 3 and Online Figure 1.
The prevalence of candidate variants in FHOD3 was
higher in the HCM cohort (2.32%; 47 variants in 74 of
3,189 probands) than in disease control subjects
(0.65%; 17 variants in 18 of 2,777) or in the gnomAD
database (0.76%; 587 variants in 1,049 of 138,606 in-
dividuals), with an odds ratio (OR) of 3.64 (95% con-
ﬁdence interval [CI]: 2.17 to 6.11; p < 0.001) and 3.02
(95% conﬁdence interval: 2.45 to 3.95; p < 0.001),
respectively.
SEGREGATION STUDY. Of the 74 probands with a
diagnosis of HCM, 14 were excluded because they
were carriers of additional variants in a sarcomeric
gene that could be related to the phenotype: 12 of 74
(16.2%) a pathogenic or likely pathogenic variant (9 inMYBPC3 and 3 inMYH7) and 2 of 74 (2.7%) a variant of
unknown clinical signiﬁcance (1 in MYBPC3 and 1 in
MYL2) (Online Table 4).
Finally, 49 HCM probands carrying 27 candidate
variants in FHOD3 recruited from 27 different centers
accepted to participate in the segregation phase of the
study, as shown in the study ﬂow chart (Figure 1).
Clinical assessment was possible in the relatives of 30
probands (Online Figure 2, Online Table 5). The pre-
sentation was familial (at least 1 affected family
member) in 25 families (83%), and 5 cases (17%) were
sporadic (there was no family history, and none of the
evaluated relatives were affected).
After clinical evaluation and genotyping of 129
members from 25 families, a ﬁnal combined LOD
score of 7.92 was obtained, equivalent to a
p value <3  107, indicative of very strong cose-
gregation (Online Table 6) (9). A total of 13 variants
were considered pathogenic or very likely patho-
genic; in all of them, there was evidence of cose-
gregation with HCM in at least 1 family (Online
Table 7). Disease-causing variants were distributed
in 35 HCM probands without additional variants that
could explain the disease in sarcomeric genes,
FIGURE 3 Molecular Organization of FHOD3 Protein and Relevant Domains for Actin Binding and Protein-Protein Interactions
A
B
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18 40
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(A) The distribution across the FHOD3 protein of the mutations considered pathogenic/likely pathogenic (blue, top) and of uncertain signiﬁcance (green, bottom) in
HCM patients who participated in the segregation study. (B) The same distribution can be observed in the schematic representation of the protein, with the addition of
the variants detected in HCM probands who did not participate in the Segregation Phase of the study (orange). The intramolecular interaction between the DID and DAD
domains, which prevents formin from nucleating actin ﬁlaments, is relieved by the phosphorylation of serine/threonine DAD residues by the ROCK protein (B). The
regulation of dimerization to an active state may be more complex, including a dimerization domain (DD). Although in some formin proteins, such as FHOD1 and
mDia1, DID and DD domains are clearly concentrated in speciﬁc regions, in FHOD3 it could be more complex and involve a wider zone (pink). CCR ¼ coiled-coil region;
DAD ¼ diaphanous auto-regulatory domain; DD ¼ dimerization domain; DID ¼ diaphanous inhibitory domain; FH ¼ formin homology domain; GBD ¼ GTPase-binding
domain.
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2462representing 1.1% (35 of 3,189) of the entire HCM
cohort.
In 6 families, segregation analysis was uncertain,
and was unlikely in 2 (the probands were carriers of
the variants p.Lys371Arg and p.Glu832Lys) (Online
Figure 2, panel 1B). It was not possible to determine
the pathogenicity of 14 variants that were ﬁnally
classiﬁed as of unknown clinical signiﬁcance.
The most commonly identiﬁed variants affected
consecutive amino acids. The variant p.Tyr528Cys
was identiﬁed in 6 probands, 4 of whom came from
the same region of Spain and were proved to be de-
scendants of a common ancestor born 7 generations
ago (Figure 2). In this multigenerational family, the
variant cosegregated with the disease with the high-
est LOD score (3.82) for an individual family. Theother 2 probands came from centers from the United
Kingdom and Denmark. The variant p.Ser527del,
affecting the previous residue, was detected in 12
HCM probands from different geographical areas in
Spain, Denmark, and the United Kingdom as well.
None of these probands had additional variants in
sarcomeric genes that could explain the disease, and
cosegregation with the phenotype was conﬁrmed in
the 5 families with relatives available for evaluation.
Among the remaining variants, 7 were clustered in a
conserved small coiled-coil domain (amino acids
622 to 655) (Figure 3A, Online Figure 3). The OR of
the presence of a candidate variant in FHOD3 in
this coiled-coil domain in HCM was 21.8 against
control subjects (95% conﬁdence interval [CI]: 1.3 to
37.9; p < 0.001) and 14.1 against gnomAD individuals
TABLE 1 Clinical Characteristics of HCM Patients Carrying Pathogenic or Likely
Pathogenic Variants in FHOD3 Stratiﬁed by Sex
Overall
(N ¼ 70)
Male
(n ¼ 43)
Female
(n ¼27) p Value
Cardiac structural affection
HCM subtype
Septal asymmetric 35/41 (85.4) 22/25 (88) 13/16 (81.3) NS
Concentric 4/41 (9.8) 2/25 (8.0) 2/16 (12.5) NS
Apical 2/41 (6.3) 1/25 (4.0) 1/25 (4.0) NS
LVMWT, mm 18.8  5.4 18.9  5.4 18.6  5.6 NS
LVMWT >30 mm 3/64 (4.7) 1/39 (2.6) 2/25 (8.0) NS
LVMWT >25 mm 7/64 (10.9) 4/39 (10.3) 3/25 (12.0) NS
LV dilatation 2/55 (3.6) 0/31 (0.0) 2/24 (8.3) NS
LVEDD, mm 45.7  5.9 46.8  5.2 43.8  6.7 NS
LV dysfunction (EF <50%) 6/46 (13.0) 1/25 (4.0) 5/21 (23.8) 0.079
EF, % 61.5  11.9 64.8  8.5 57.5  14.2 0.046
Hypertrabeculation 8/49 (16.4) 5/27 (18.5) 3/22 (13.6) NS
Positive LVNC criteria 4/49 (8.2) 1/27 (3.7) 3/22 (13.6) NS
Negative LVNC criteria 4/49 (8.2) 4/27 (14.8) 0/22 (0.0) NS
LA dilatation 19/39 (48.7) 11/22 (50.0) 8/17 (47.1) NS
LA, mm 41.7  8 44.4  8.2 38.2  7.9 0.026
LVOTO 9/42 (21.4) 4/24 (16.7) 5/18 (27.8) NS
SAM (MV) 5/40 (12.5) 4/22 (18.2) 1/18 (5.6) NS
CMR LGE 11/17 (64.7) 6/10 (60.0) 5/7 (71.4) NS
ECG and arrhythmias
ECG rhythm
Sinus rhythm 48/55 (87.3) 26/30 (86.7) 22/25 (88.0) NS
Atrial ﬁbrillation 6/55 (10.9) 4/30 (13.3) 2/25 (8.0) NS
Pacemaker 1/55 (1.8) 0/30 (0.0) 1/25 (4.0) NS
ECG LVH 39/49 (79.6) 19/27 (70.4) 20/22 (90.9) 0.076
Atrial ﬁbrillation history
Permanent 8/58 (13.8) 5/33 (15.2) 3/25 (12.0) NS
Paroxysmal 3/58 (5.2) 0/33 (0.0) 3/25 (12.0) NS
NSVT 11/41 (26.8) 4/23 (17.4) 7/18 (38.9) NS
Frequent PVC 6/40 (15.0) 3/23 (13.0) 3/17 (17.6) NS
ICD implanted 10/58 (17.2) 5/33 (15.2) 5/25 (20.0) NS
History and symptoms
Age at diagnosis 46.1  18.7 43.6  18.2 50.9  19.2 0.047
Hypertension 8/43 (18.6) 3/26 (11.5) 5/17 (29.4) NS
Dyspnea
NYHA functional class II 19/59 (32.2) 9/34 (26.4) 10/25 (40.0) NS
NYHA functional class III–IV 6/59 (10.1) 1/34 (2.9) 5/25 (20.0) 0.069
Syncope 5/56 (8.9) 4/31 (12.9) 1/25 (4.0) NS
Events
Cardiovascular death (overall) 13/68 (19.1) 10/41 (24.4) 3/27 (11.1) NS
Sudden cardiac death 11/68 (16.2) 9/41 (22.0) 2/27 (7.4) NS
Heart failure death/heart
transplantation
2/68 (2.9) 1/41 (2.4) 1/27 (3.7) NS
Stroke 5/64 (7.8) 2/38 (5.3) 3/26 (11.5) NS
Values are n/N (%) or mean  SD.
CMR LGE ¼ late-gadolinium enhancement in magnetic resonance images; ECG ¼ electrocardiogram;
EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; LA ¼ left atrium; LV ¼ left ventricle;
LVEDD ¼ left ventricular end-diastolic diameter; LVH ¼ left ventricular hypertrophy; LVMWT ¼ maximal
left ventricular wall thickness; LVNC ¼ left ventricular noncompaction; LVOTO ¼ left ventricular
outﬂow tract obstruction; NSVT ¼ nonsustained ventricular tachycardia; NYHA ¼ New York Heart
Association; PVC ¼ premature ventricular contractions; SAM (MV) ¼ systolic anterior movement of the mitral
valve.
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2463(95% CI: 6.9 to 28.7; p < 0.001). The complete list of
the pathogenic or likely pathogenic variants and the
distribution along the FHOD3 protein is summarized
in Figure 3A. The variants identiﬁed in control sub-
jects or in phenotypes other than HCM were
randomly distributed throughout the gene, but none
of them was identiﬁed in the coiled-coil domain or
affecting residues 527 to 528 (Online Figure 1).
Only 2 truncating variants in FHOD3 were identi-
ﬁed in HCM cases: p.Lys1433Serfs*10 and p.Arg1597*.
Both were present at very low frequencies in control
subjects (MAF% 0.002 and 0.0004, respectively). The
p.Lys1433Serfs*10 variant was identiﬁed in a patient
who carried an additional variant, p.Arg17Gln, in
MYBPC3; although it was excluded from the analysis,
segregation was evaluated in the family, but the re-
sults were inconclusive (Online Figure 2). The
nonsense variant p.Arg1597* was identiﬁed in 2 pro-
bands: 1 was a sporadic case with a nonsevere
phenotype diagnosed after age 75 years and the sec-
ond was a patient with restrictive cardiomyopathy
(the variant did not segregate with the disease in this
family). Both variants were considered of uncertain
signiﬁcance.
CLINICAL CHARACTERISTICS OF HCM PATIENTS
CARRYING DISEASE-CAUSING VARIANTS IN
FHOD3. Demographic, clinical, echocardiographic,
and electrocardiographic characteristics of HCM car-
riers of disease-causing variants in FHOD3 are shown
in Table 1. Two-thirds (66.7%) of the probands were
males; this predominance was also observed in
affected relatives (56.8% vs. 43.2%). There was no
difference in the age at diagnosis between index cases
and relatives. Most of the patients were diagnosed
after age 30 years (median 58 years in women and 48
years in men). Incomplete penetrance was observed:
at age 70 years, 15% of men and 32% of women were
clinically unaffected (Figure 4A).
Approximately 40% of the patients were symp-
tomatic, with dyspnea as the most common symp-
tom. The predominant HCM subtype was asymmetric
septal hypertrophy (82%). The degree of hypertrophy
was mild to moderate (mean 18.8  5 mm), and the
presence of massive hypertrophy ($30 mm) was
exceptional. Left ventricular outﬂow tract obstruc-
tion and systolic anterior movement of the mitral
valve were present in 21% and 12.5% of the patients,
respectively. Left ventricular systolic dysfunction
(ejection fraction <50%) was described in 14% of the
patients. Hypertrabeculation of the left ventricle was
present in 16% (8 of 49) of the patients, one-half of
FIGURE 4 Cumulative Distribution of Age at Diagnosis and Survival Free of
Cardiovascular Death During Follow-Up After the Diagnosis of HCM
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(A) The cumulative distribution of age at diagnosis (penetrance) stratiﬁed by sex. (B) The
freedom from cardiovascular death of the patients after a diagnosis of HCM was made
(only affected carriers with clinical follow-up are included in this analysis). FHOD3 ¼
formin homology 2 domain containing 3 gene; HCM ¼ hypertrophic cardiomyopathy.
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2464whom (4 of 49; 8%) fulﬁlled the criteria for left ven-
tricular noncompaction.
EVENTS. A total of 13 of the 81 carriers/affected rel-
atives (16%) experienced a cardiovascular death. The
incidence was higher in men (10 of 48; 20.1%) than inwomen (3 of 33; 7.3%), but did not reach statistical
signiﬁcance (p ¼ 0.16). Events were rare before the
age of 30 years. The annual cardiovascular death
incidence after the diagnosis of HCM was approxi-
mately 1% per year (Figure 4B) with a median of
follow-up of 5 years in the group (range 1.8 to 18
years). SCD was the most frequent cause (11 of 13;
85%), being the ﬁrst manifestation of the disease in 4
probands; the diagnosis was made after successful
resuscitation from cardiac arrest in 2 and on autopsy
in 2 other cases, 1 of whom was a compound hetero-
zygous carrier of p.Arg1386Gln and p.Pro615Leu in
FHOD3 (Online Figure 2). The other 7 were relatives in
whom genetic testing was unavailable. Two patients
(2 of 13; 15%) experienced heart failure death: a 58-
year-old woman who had a concomitant diagnosis
of rheumatic severe mitral stenosis and a 37-year-old
man with a restrictive ﬁlling pattern.
DISCUSSION
In this study, we demonstrated a clear relationship
between FHOD3 mutations and the development of
HCM (Central Illustration). Almost 7,800 probands
were screened for the presence of very rare candidate
variants in FHOD3, and an excess of these variants in
the HCM cohort with respect to control subjects was
observed (OR: 3). This ratio is lower than those ob-
tained by other groups using the same approach for
nontruncating variants in MYBPC3 (OR: 5.7) or MYH7
(OR: 12) (7), reﬂecting that not all of the very rare
candidate variants in FHOD3 are necessarily associ-
ated with disease. As in other sarcomeric genes, it is
difﬁcult to predict if a novel nontruncating variant
is pathogenic or not; in these cases, segregation
analysis in the family is mandatory. In our study,
cosegregation of several variants in FHOD3 was
conﬁrmed, yielding a combined LOD score of 7.95,
which is indicative of very strong cosegregation
(highly signiﬁcant linkage) (10). Disease-causing var-
iants in FHOD3 accounted for at least 1% of HCM
cases. Taking into account that in this study we used
a very strict strategy to consider a variant disease-
causing (only variants with evidence of segregation),
that segregation was evaluable in only one-half of the
candidate variants, and that cases with additional
potentially pathogenic variants in other sarcomeric
genes were excluded, it is likely that FHOD3 muta-
tions account for approximately 2% of HCM cases
and 4% of positive genetic studies. This prevalence
would be similar to or greater than the reported
prevalence of mutations in established sarcomeric
protein genes, such as TPM1, MYL2, MYL3, ACTC1,
and TNNC1 (11,12).
CENTRAL ILLUSTRATION FHOD3 is a Novel Disease-Causing Gene in HCM
Ochoa, J.P. et al. J Am Coll Cardiol. 2018;72(20):2457–67.
Diagram illustrating the results and main messages of the study. Around 50% of the genetic tests performed in hypertrophic cardiomyopathy (HCM) are negative;
FHOD3 plays a role in sarcomere organization, but was considered only a candidate gene. After evaluating >7,800 probands, we identiﬁed disease-causing variants in
FHOD3 cosegregating with HCM in several families and accounting for approximately 1% to 2% of HCM cases. FHOD3 should be routinely included in HCM genetic
testing panels. FHOD3 ¼ formin homology 2 domain containing 3 gene; LOD ¼ logarithm of the odds.
J A C C V O L . 7 2 , N O . 2 0 , 2 0 1 8 Ochoa et al.
N O V E M B E R 1 3 / 2 0 , 2 0 1 8 : 2 4 5 7 – 6 7 FHOD3 is an HCM-Causing Gene
2465The phenotype associated with FHOD3 mutations
in our study was relatively mild, with a low rate of
adverse events in young individuals and an overall
rate of cardiovascular endpoints similar to that
described in unselected HCM patient cohorts (12,13).
Two-thirds of the index cases were men, and the
diagnosis in female carriers was made 10 years later
than in males. Late onset of the disease and incom-
plete penetrance were observed in both sexes.
The association between FHOD3 and HCM has
been postulated in a GWAS study (5). The authors
identiﬁed 2 frequent polymorphisms in FHOD3
(1 deep intronic variant and the missense variant
p.Val1326Ile, both with MAFs $30%) that were more
frequent in HCM cases than in control subjects, but
failed to demonstrate a difference in phenotype
expression between homozygous and heterozygous
carriers of the p.Val1326Ile variant. These ﬁndings
can be considered an association (a signal in theGWAS study) between the gene and the phenotype,
but no description of any variant in FHOD3 causing
HCM has been published to date. The explanation for
this might be that most diagnostic laboratories do
not include FHOD3 in their sequencing panels; thus,
very rare protein-altering candidate variants are not
being identiﬁed. Alternatively, it can be difﬁcult to
detect an association in a GWAS when mild pheno-
types with incomplete penetrance are present, and
this type of study focuses on detecting frequent
polymorphisms but is not designed to detect very
rare variants.
A possible association of FHOD3 mutations with
DCM has also been suggested; there is a report of a
small Japanese family (only 2 members were geno-
typed) in whom an in vivo functional study showed
that the identiﬁed variant impaired actin ﬁlament
assembly (14), and previous functional studies in
animal models have demonstrated that FHOD3 plays
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2466a role in heart development (15). Similarly, an exome-
wide association study identiﬁed FHOD3 as 1 of 8 loci
independently associated with sporadic DCM (16).
Our study was not designed to determine the possible
causal relationship between FHOD3 and DCM. Of the
130 probands carrying candidate variants in FHOD3,
18 had this phenotype (they were excluded in the
screening phase of the study). These variants were
not clustered in any particular region of the gene, and
most of them were classiﬁed as of uncertain signiﬁ-
cance at initial evaluation. Further studies are needed
to establish the clinical relevance of FHOD3 muta-
tions and their relationship to DCM.
The relationship between FHOD3 and ventricular
hypertrophy has been recently explored in a study of
angiotensin II–induced cardiac hypertrophy (17).
Under basal conditions, the FHOD3 protein exists in
an auto-inhibited state due to the interaction be-
tween its diaphanous autoregulatory domain and the
diaphanous inhibitory domain (Figure 3B). The
phosphorylation of speciﬁc phospho-acceptor resi-
dues located in the autoregulatory domain (Ser1590,
Ser1596, and Thr1600) by the RhoA/ROCK pathway
seems to inhibit the interaction with the inhibitory
domain, allowing the FHOD3 protein to form active
dimers that enable actin nucleation and assembly
of myoﬁbrils in cardiomyocytes, thereby causing
cellular hypertrophy (18). Several FHOD3 candidate
variants in this study were located in the autor-
egulatory and inhibitory domains or their surround-
ing residues (Figure 3A, Online Figure 1); 1
hypothesis is that these mutations alter the normal
interaction, leading to a predominance of FHOD3
protein in an activated state, a mechanism that has
been described for mutations in the paralogue
FHOD1 (19,20).
FHOD3 protein dimerization to an activated state
may be more complex, including a dimerization
domain and a helical region (coiled-coil domain) that
forms a cross-bridge between the opposing chains
and provides the conformational ﬂexibility required
for the stair-stepping actin polymerization mecha-
nism (21). One-half of the disease-causing variants
found in our study were located in the coiled-coiled
domain that seems to be speciﬁc for a HCM pheno-
type (no disease controls or patients with cardiomy-
opathies other than HCM where identiﬁed in it). The
exact location and functional characterization of the
inhibitory and dimerization domains in FHOD3 are
still not well understood; 2 clearly pathogenic vari-
ants that cosegregated with HCM in several families
(p.Ser527del and p.Tyr528Cys) were found near these
domains. They also affect an exon that is only present
in the longest transcript of FHOD3, which is currentlyconsidered the most important isoform in the adult
ventricular myocardium, because it contains an
additional exon that is required for targeting the
FHOD3 protein to the myoﬁbrils in cardiomyocytes
(22). Our ﬁndings support the relevance of this iso-
form in the pathogenesis of HCM, although functional
studies are needed to determine the exact mecha-
nisms underlying the development of HCM in FHOD3
mutation carriers.
STUDY LIMITATIONS. One of the limitations of our
study is that segregation was limited in some families
because of the small number of relatives available for
screening, and clinical assessment was incomplete in
some carriers. Another possible limitation is that pa-
tients were screened only for genes previously asso-
ciated with inherited cardiac conditions; therefore,
the presence of mutations in other genes contributing
to the phenotype cannot be ruled out.
CONCLUSIONS
In this study, we have demonstrated that FHOD3 is a
novel disease-causing gene in HCM. Pathogenic mu-
tations would account for approximately 1% to 2% of
HCM cases, a prevalence that is similar or greater to
that described in other secondary sarcomeric protein
genes. The associated phenotype and the rate of
cardiovascular events are similar to that described for
unselected cohorts of patients with HCM; thus, a
clinical follow-up is recommended in affected car-
riers. The FHOD3 gene should be routinely included
in genetic testing panels for HCM.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: FHOD3
accounts for approximately 1% to 2% of cases of HCM,
and its prevalence is similar to or greater than that of
mutations in established sarcomeric protein genes.
TRANSLATIONAL OUTLOOK: Collaborative studies of
a larger number of patients are necessary to identify an
association with other phenotypes and expose mecha-
nisms underlying the development of HCM in carriers of
FHOD3 disease-causing variants.
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research centers (genetics, molecular biology,
and data-analysis) of the GENESCOPIC research
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